Company

Lineage Cell Therapeutics, Inc. (LCTX)

Standardized SEC financial data for Lineage Cell Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000876343 · NYSE · Biological Products, (No Diagnostic Substances).

Gross margin

63.0%

Operating margin

-251.6%

Net margin

-436.5%

Revenue growth (YoY)

53.2%

Return on equity

-146.6%

ROIC

-1000.0%

Free cash flow

-$19.4M

Debt / equity

0.00×

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.8M	$4.3M	$14.7M	$8.9M	$9.5M	$14.6M
Cost of revenue	$385K	$1.4M	$728K	$671K	$334K	—
Gross profit	$1.4M	$2.9M	$14.0M	$8.3M

Balance sheet

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$41.6M	$58.4M	$11.9M	$36.0M	$46.4M	$41.3M
Total current assets	$44.0M	$111.5M	$60.0M	$38.4M	$51.0M	$59.2M
Property, plant & equipment	$5.6M	$4.9M	$5.7M	$2.2M

Cash flow

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$19.8M	-$23.6M	$1.1M	-$28.6M	-$23.1M	-$18.9M
Capital expenditures	$64K	$340K	$413K	$674K	$565K	$522K
Free cash flow	-$19.8M	-$23.9M	$646K	-$29.2M

Get LCTX data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/LCTX/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/LCTX/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View LCTX filings on SEC EDGAR →